Table 2.
Survival of patients by metastatic site combination
| Metastatic site combination | n (%) | mOS | 95% CI |
|---|---|---|---|
| Unknown | 10 059 (23.7) | 7.0 | 6.72–7.28 |
| Lung | 5538 (13.1) | 9.0 | 8.55–9.44 |
| Brain | 5463 (12.9) | 7.0 | 6.70–7.30 |
| Lung + Brain | 1433 (3.4) | 6.0 | 5.50–6.50 |
| Bone | 7218 (17.0) | 7.0 | 6.73–7.27 |
| Lung + Bone | 2536 (6.0) | 6.0 | 5.57–6.43 |
| Brain + Bone | 2136 (5.0) | 5.0 | 4.65–5.36 |
| Lung + Brain + Bone | 1027 (2.4) | 5.0 | 4.51–5.49 |
| Liver | 1503 (3.5) | 5.0 | 4.47–5.53 |
| Lung + Liver | 645 (1.5) | 4.0 | 3.41–4.59 |
| Brain + Liver | 424 (1.0) | 4.0 | 3.54–4.46 |
| Lung + Brain + Liver | 227 (0.5) | 3.0 | 2.39–3.61 |
| Bone + Liver | 1743 (4.1) | 4.0 | 3.72–4.23 |
| Lung + Bone+ Liver | 1055 (2.5) | 4.0 | 3.67–4.33 |
| Brain + Bone + Liver | 735 (1.7) | 4.0 | 3.50–4.50 |
| Lung + Brain + Bone + Liver | 656 (1.5) | 4.0 | 3.51–4.49 |
CI, confidence interval; mOS, median overall survival.